Shen T, Yang F, Wu J, Qin Y, Zhou X, Zhao X
J Fluoresc. 2025; .
PMID: 39776097
DOI: 10.1007/s10895-024-04105-w.
Serifoglu H, Arinkan S, Pasin O, Vural F
Rev Assoc Med Bras (1992). 2023; 69(6):e20221679.
PMID: 37255083
PMC: 10234359.
DOI: 10.1590/1806-9282.20221679.
Lee J, Lee D
Ophthalmol Ther. 2023; 12(4):1851-1863.
PMID: 36907949
PMC: 10287614.
DOI: 10.1007/s40123-023-00696-y.
Xie H, Chen D, Zhang J, Yang R, Gu W, Wang X
Front Public Health. 2022; 10:993733.
PMID: 36304250
PMC: 9592843.
DOI: 10.3389/fpubh.2022.993733.
Fang Y, Du W, Zhang C, Zhao S, Song H, Gao G
BMC Endocr Disord. 2021; 21(1):238.
PMID: 34847904
PMC: 8630916.
DOI: 10.1186/s12902-021-00905-4.
Non-Conventional Clinical Uses of TSH Receptor Antibodies: The Case of Chronic Autoimmune Thyroiditis.
Napolitano G, Bucci I, Di Dalmazi G, Giuliani C
Front Endocrinol (Lausanne). 2021; 12:769084.
PMID: 34803929
PMC: 8602826.
DOI: 10.3389/fendo.2021.769084.
Natural autoantibodies to the gonadotropin-releasing hormone receptor in polycystic ovarian syndrome.
Sattler L, Schniewind H, Minich W, Haudum C, Niklowitz P, Munzker J
PLoS One. 2021; 16(4):e0249639.
PMID: 33798258
PMC: 8018624.
DOI: 10.1371/journal.pone.0249639.
Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) - one step less, similar results?.
Roggenbuck J, Zarske G, Schierack P, Wunderlich G, Conrad K, Kotzerke J
Nuklearmedizin. 2021; 60(1):38-46.
PMID: 33535269
PMC: 7857932.
DOI: 10.1055/a-1277-5972.
The Clinical Value and Variation of Antithyroid Antibodies during Pregnancy.
Li C, Zhou J, Huang Z, Pan X, Leung W, Chen L
Dis Markers. 2020; 2020:8871951.
PMID: 33144894
PMC: 7599418.
DOI: 10.1155/2020/8871951.
DYNAMIC CHANGES OF TRAb AND TPOAb AFTER RADIOIODINE THERAPY IN GRAVES' DISEASE.
Dong Q, Liu X, Wang F, Xu Y, Liang C, Du W
Acta Endocrinol (Buchar). 2019; 13(1):72-76.
PMID: 31149151
PMC: 6525742.
DOI: 10.4183/aeb.2017.72.
A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody.
Roggenbuck J, Veiczi M, Conrad K, Schierack P, Wunderlich G, Kotzerke J
Immunol Res. 2019; 66(6):768-776.
PMID: 30684216
DOI: 10.1007/s12026-018-9062-z.
Thyrotropin Receptor Blocking Antibodies.
Diana T, Olivo P, Kahaly G
Horm Metab Res. 2018; 50(12):853-862.
PMID: 30286485
PMC: 6290727.
DOI: 10.1055/a-0723-9023.
Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S, Ashida K, Nagata H, Ohe K, Wada N, Takeichi Y
BMC Endocr Disord. 2018; 18(1):36.
PMID: 29884162
PMC: 5994101.
DOI: 10.1186/s12902-018-0267-x.
Epidemiology, management and outcomes of Graves' disease-real life data.
Hussain Y, Hookham J, Allahabadia A, Balasubramanian S
Endocrine. 2017; 56(3):568-578.
PMID: 28478488
PMC: 5435772.
DOI: 10.1007/s12020-017-1306-5.
Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N, Kaneko M, Kitazawa M, Uemura Y, Minagawa S, Miyakoshi M
J Med Case Rep. 2017; 11(1):32.
PMID: 28162094
PMC: 5292792.
DOI: 10.1186/s13256-017-1214-6.
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease.
Kwon H, Kim W, Jang E, Kim M, Park S, Jeon M
Endocrinol Metab (Seoul). 2016; 31(2):300-10.
PMID: 27118279
PMC: 4923415.
DOI: 10.3803/EnM.2016.31.2.300.
Graves Disease Is Associated With Endometriosis: A 3-Year Population-Based Cross-Sectional Study.
Yuk J, Park E, Seo Y, Kim H, Kwon S, Park W
Medicine (Baltimore). 2016; 95(10):e2975.
PMID: 26962803
PMC: 4998884.
DOI: 10.1097/MD.0000000000002975.
"Orbiting around" the orbital myositis: clinical features, differential diagnosis and therapy.
Montagnese F, Wenninger S, Schoser B
J Neurol. 2015; 263(4):631-40.
PMID: 26477021
DOI: 10.1007/s00415-015-7926-x.
Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer.
Kemal Y, Demirag G, Ekiz K, Yucel I
Mol Clin Oncol. 2015; 3(3):629-632.
PMID: 26137279
PMC: 4471579.
DOI: 10.3892/mco.2015.521.
High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
Hwang S, Shin D, Song M, Lee E
Endocrine. 2014; 48(1):89-95.
PMID: 24968734
DOI: 10.1007/s12020-014-0325-8.